ARQL - ArQule: With Its Developing R&D Pipeline We Are Looking For A Pullback
ArQule, Inc. (ARQL) is a clinical stage pharmaceutical company pursuing multiple programs in biomarker-defined oncology and rare disease indications.
ARQL stock saw some action in the last session, trading over 3 times of average volume at a 6% increase from the previous close. We will see why the stock is attracting market attention and if it is justified.
Catalyst
The immediate catalyst that triggered the market enthusiasm is the October 2, 2019, announcement of initiation of dosing in the phase 1/2 MOSAIC trial for ARQ 092 (miransertib) in overgrowth diseases. Topline data from this trial